Clinical Trial

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).
Protocol Amendment History 1 change
notable Trial sites expanded: 212 -> 215 locations 2026-07-11
Trial Details
NCT Number NCT06422143
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer, NSCLC
Enrollment 851 participants
Start Date 2024-06-10
Primary Completion 2029-01-12 (estimated)
Study Completion 2031-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07